4D Pharma (LON:DDDD) Trading 5% Higher
4D Pharma (LON:DDDD) Trading 5% Higher
4D pharma plc, together with its subsidiaries, develops live biotherapeutic products (LBPs) in the United Kingdom. The company develops therapeutic candidates, including MRx0518 for the treatment of cancer and immune-oncology diseases; MRx-4DP0004 for the treatment of asthma; MRx0029 and MRx0005 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease.4D pharma plc (LON:DDDD – Get Rating)'s share price traded up 5% on Tuesday . The stock traded as high as GBX 16.86 ($0.20) and last traded at GBX 16.66 ($0.20). 912,370 shares were traded during mid-day trading, a decline of 69% from the average session volume of 2,957,490 shares. The stock had previously closed at GBX 15.86 ($0.19).
4D 製藥有限公司（LON：DDDD-獲取評級）的股價在星期二上漲了 5％。該股交易高達 16.86 英鎊（0.20 美元），最後交易價格為 16.66 英鎊（0.20 美元）。在中午交易期間交易了 912,370 股，較平均交易時段成交量 2,957,490 股下跌 69%。該股票之前已收盤 15.86 英鎊（0.19 美元）。
4D pharma Stock Performance
4D 製藥股票表現
The company has a debt-to-equity ratio of 39.50, a current ratio of 5.21 and a quick ratio of 4.72. The firm has a market cap of £30.04 million and a price-to-earnings ratio of -1.08. The company has a fifty day moving average price of GBX 16.66 and a two-hundred day moving average price of GBX 27.35.
該公司的債務與權益比率為 39.50，流動比率為 5.21，快速比率為 4.72。該公司的市值為 30.04 萬英鎊，價格盈利比為 -1.08。該公司擁有五十天的移動平均價格 GBX 16.66 英鎊，兩百天移動平均價格為 27.35 英鎊。
4D pharma Company Profile
4D 製藥公司簡介
(Get Rating)
(取得評分)
4D pharma plc, together with its subsidiaries, develops live biotherapeutic products (LBPs) in the United Kingdom. The company develops therapeutic candidates, including MRx0518 for the treatment of cancer and immune-oncology diseases; MRx-4DP0004 for the treatment of asthma; MRx0029 and MRx0005 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease.
4D 製藥 plc 及其子公司在英國開發活生物治療產品（LBP）。該公司開發治療候選人，包括用於治療癌症和免疫腫瘤疾病的 MrX0518；用於治療哮喘的 MRX 4dp0004；治療中樞神經系統疾病的 MRX0029 和 mRX0005；Blautix 用於腸易激綜合徵；以及兒科克羅恩病的 Thetanix。
Featured Articles
特色文章
- 3 Alzheimer Stocks to Buy as the Race for a Cure Heats Up
- Don't Forget About These Cheap, Fundamentally Strong Tech Stocks
- Bellwether RPM International Pops On Results
- Rivian Checks Off Boxes, But Still Needs a Lot to Go Right
- Hot Potato: Lamb Weston Stock Confirms a Top
- 3 種阿爾茨海默氏症股票在尋求治愈的競賽中購買升溫
- 不要忘記這些廉價，從根本上強大的科技股
- 貝爾韋瑟 RPM 國際流行音樂結果
- Rivian 檢查了盒子，但仍然需要很多東西才能向右走
- 熱土豆：羊肉韋斯頓股票確認頂部
Receive News & Ratings for 4D pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4D pharma and related companies with MarketBeat.com's FREE daily email newsletter.
每日接收 4D 製藥的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 4D 製藥及相關公司的最新新聞和分析師評級的簡明每日摘要。
譯文內容由第三人軟體翻譯。
